查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1976587

抗菌敷料市场：按敷料类型、药物类型、伤口类型和最终用户划分 - 全球预测 2026-2032

Antimicrobial Dressings Market by Dressing Type, Agent Type, Wound Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗菌敷料市场价值将达到 16.4 亿美元，到 2026 年将成长至 17.5 亿美元，到 2032 年将达到 26.5 亿美元，复合年增长率为 7.07%。

主要市场统计数据
基准年 2025 16.4亿美元
预计年份：2026年 17.5亿美元
预测年份 2032 26.5亿美元
复合年增长率 (%) 7.07%

简要概述抗菌敷料技术、临床驱动因素、采购压力以及影响采用决策的不断变化的环境。

抗菌敷料融合了临床需求、材料创新和供应链韧性，本执行摘要总结了关键见解，旨在为医疗系统领导者、产品负责人和分销合作伙伴提供参考。支持这些敷料的技术涵盖了从蜂蜜和碘等传统抗菌剂到PHMB和银等现代化学物质，敷料形式也多种多样，包括藻酸盐和泡沫敷料、薄膜敷料和水凝胶敷料。敷料设计的进步源于降低感染率、加速创伤治疗以及减轻门诊和住院患者整体医疗负担的需求。

临床需求、材料创新、监管加强和医疗服务分散化的整合正在如何重塑抗菌敷料生态系统？

由于临床、技术和监管趋势的融合，抗菌敷料领域正经历变革。在临床上，预防医疗设备相关感染和伤口相关感染变得日益重要，这加速了兼具抗菌活性和适用于湿性伤口护理及清洁特性的敷料的应用。在技​​术上，从先进的银涂层到稳定的聚甲基丙烯酸甲酯（PHMB）基质和生物活性蜂蜜衍生物，配方和递送方法的创新正在带来更稳定的抗菌效果，同时提高患者的舒适度和延长敷料的使用时间。

本研究评估了美国在 2025 财政年度宣布的关税调整对抗菌敷料供应链和采购的影响，以及策略供应商的应对措施。

美国宣布的2025财政年度关税调整方案，为抗菌敷料的采购和供应链规划引入了新的变数。特种纤维、银化合物和聚合物薄膜等原料在生产过程中往往需要多次跨境运输，进口关税和海关程序的变化可能导致到岸成本增加和交货前置作业时间延长。为此，供应商正在重新评估其采购地点，尽可能优先选择邻近地区的生产，并加快对替代供应商的认证，以确保供应的连续性。

透过深入的細項分析，将绷带形态、抗菌化学物质、护理环境和伤口类型与临床应用案例和商业性管道相匹配。

細項分析揭示了敷料形式、抗菌剂、护理环境和伤口类型等方面的不同应用模式和发展重点。就敷料类型而言，相关人员评估了藻酸盐和泡棉敷料在高渗出性伤口中的应用，而薄膜和片状敷料（进一步分为亲水胶体薄膜和透明薄膜）则适用于低渗出性伤口和需要隐蔽保护的情况。水凝胶，包括无定形水凝胶和片状水凝胶，越来越多地用于自溶解性伤口清创和疼痛敏感区域。同时，粉状敷料也被证明对瘻管伤口和不规则形状伤口效用。

区域需求因素和法规的差异决定了商业策略的差异。

区域趋势显示，需求驱动因素和采用率存在差异，主要受医疗基础设施、采购惯例和法规结构的影响。在美洲，成熟的医院网路和不断扩展的门诊服务推动了对各种抗菌敷料的需求，采购者越来越重视能够缩短住院时间和降低再入院风险的循证产品。欧洲、中东和非洲地区的情况则更为复杂。虽然临床差异化和严格的监管合规性是西方市场关注的重点，但在中东和非洲的许多市场，成本控制和供应稳定性才是主导驱动因素，这促使人们对耐用且易于储存的敷料产生兴趣。

透过建立临床证据、策略伙伴关係和附加价值服务模式，促进创伤护理产品组合供应商之间的差异化。

竞争格局呈现出多元化的特点，包括专业医用敷料公司、大型医疗保健集团旗下的多元化创伤护理部门，以及专注于新型抗菌化学技术的新兴利基企业。主要企业正致力于产生临床证据并进行上市后监测，以支持其降低感染率和加速癒合的说法。与学术机构和大型医疗保健系统的策略合作正在推动真实世界证据 (RWE) 的累积和临床路径的製定，从而支持药物上市申请。

为製造商和买家提供可操作的策略重点，将临床证据、供应弹性、综合服务和以结果为导向的采购连结起来。

产业领导者应优先考虑切实可行的措施，使商业性可行性与临床价值和供应的稳定性一致。首先，投资于可操作的临床证据项目，以解决医院药房委员会和居家医疗提供者提出的关于感染率、佩戴时长和患者依从性的具体问题。实用、在地化且经济效益显着的证据比孤立的实验室数据更具说服力。其次，考虑实现采购来源多元化，并将关键材料近岸外包，以降低关税风险并控制前置作业时间波动。

我们透过透明且可重复的混合调查方法框架来支持可操作的见解，该框架结合了临床证据、相关人员访谈和供应链检验。

支持这些发现的研究途径包括对同侪审查的临床文献、监管指导文件和采购政策声明进行系统性回顾，以及对临床医生、采购负责人和供应链经理的访谈。研究重点在于将临床论点与实际应用联繫起来，并检验供应商对近期关税和供应中断的应对措施。调查方法优先考虑可重复性和透明度，既从公共资料库中获取定量信息，也从一线利益相关人员那里获取定性细节。

抗菌敷料长期应用临床创新、采购改善与供应弹性概述

总而言之，抗菌敷料在感染预防和伤口管理中仍然发挥着至关重要的作用，但其未来发展轨迹将受到临床证据要求、供应链韧性保障以及不断发展的医疗服务模式融合等因素的影响。药物化学性质和敷料形式的创新正在拓展治疗选择，而日益严格的监管和精细化的采购流程则提高了抗菌敷料广泛应用所需的证据标准。医疗服务向诊所和居家医疗机构分散化是一个持续的趋势，并将继续影响产品设计重点和商业性策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗菌敷料市场－依敷料类型划分

  • 海藻酸盐
  • 薄膜
    • 亲水胶体膜
    • 透明薄膜
  • 形式
  • 凝胶
  • 水凝胶
    • 非晶质水凝胶
    • 片状水凝胶
  • 粉末

第九章：按药物类型分類的抗菌敷料市场

  • 蜂蜜
  • 碘
  • 银

第十章：按伤口类型分類的抗菌敷料市场

  • 急性伤口
  • 烧伤
  • 慢性伤口

第十一章：抗菌敷料市场：依最终用户划分

  • 诊所
  • 居家医疗
  • 医院
    • 私立医院
    • 公立医院

第十二章：抗菌敷料市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：抗菌敷料市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：抗菌敷料市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国抗菌敷料市场

第十六章：中国抗菌敷料市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3M Company
  • B. Braun Melsungen AG
  • Cardinal Health
  • Coloplast A/S
  • ConvaTec Group plc
  • Essity AB
  • MedCu Technologies Ltd.
  • Medline Industries, LP
  • Molnlycke AB
  • Paul Hartmann AG
  • Smith & Nephew plc
  • Solventum Corporation
  • Urgo Medical SA
Product Code: MRR-69324464D0E3

The Antimicrobial Dressings Market was valued at USD 1.64 billion in 2025 and is projected to grow to USD 1.75 billion in 2026, with a CAGR of 7.07%, reaching USD 2.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.64 billion
Estimated Year [2026] USD 1.75 billion
Forecast Year [2032] USD 2.65 billion
CAGR (%) 7.07%

A concise orientation to antimicrobial dressing technologies, clinical drivers, procurement pressures, and the evolving landscape shaping adoption decisions

Antimicrobial dressings are at the intersection of clinical need, material innovation, and supply chain resilience, and this executive summary distils critical insights for health system leaders, product strategists, and distribution partners. The technology underpinning these dressings ranges from traditional antimicrobial agents such as honey and iodine to modern chemistries like PHMB and silver, while dressing formats extend from alginate and foam to film and hydrogel variants. Advances in dressing design are being driven by an imperative to reduce infection rates, accelerate wound healing, and lower overall care burden across outpatient and inpatient settings.

Clinicians and procurement teams alike face mounting pressure to balance cost, efficacy, and patient-centred outcomes. Consequently, products that demonstrate ease of use in clinics, adaptability for home healthcare, and robustness for hospital environments are increasingly prioritized. Regulatory pathways and reimbursement dynamics continue to influence adoption, and manufacturers are responding with data-driven claims and clinical evidence generation. In parallel, sustainability considerations and the need for supply chain transparency are shaping strategic sourcing decisions, creating conditions for differentiated players to secure advantage through clinical partnerships and validated supply reliability.

How converging clinical needs, material innovations, regulatory tightening, and care delivery decentralisation are reshaping the antimicrobial dressing ecosystem

The antimicrobial dressing landscape is undergoing transformative shifts driven by converging clinical, technological, and regulatory trends. Clinically, there is a heightened emphasis on preventing device-associated and wound-related infections, which is prompting greater adoption of dressings that combine antimicrobial activity with moisture management and debridement-friendly properties. Technologically, innovations in formulation and delivery-ranging from advanced silver coatings to stabilized PHMB matrices and bioactive honey derivatives-are enabling more consistent antimicrobial efficacy while improving patient comfort and wear time.

Concurrently, regulatory scrutiny is increasing around antimicrobial claims and safety profiles, which raises the bar for clinical evidence and post-market surveillance. This has led to an acceleration in comparative effectiveness studies and real-world evidence collection. On the supply side, manufacturers are reconfiguring sourcing strategies to reduce single-source dependencies and to build resilient production footprints. Additionally, the shift toward decentralised and home-based care is reshaping product design priorities, with greater demand for easy-to-apply, low-maintenance dressings suitable for patients and caregivers. Altogether, these trends are reorienting commercial strategies toward value demonstration, clinical partnerships, and lifecycle support services.

Assessing the supply chain and procurement consequences of United States tariff adjustments announced for twenty twenty-five and the resulting strategic supplier responses

Tariff adjustments announced by the United States for the twenty twenty-five cycle have introduced a new variable into procurement and supply chain calculations for antimicrobial dressings. Raw material inputs such as specialty fibers, silver compounds, and polymer films often cross borders several times during manufacture, and changes to import duties or customs procedures can raise landed costs and extend lead times. In response, suppliers are reassessing sourcing footprints, prioritising nearshore manufacturing where feasible, and accelerating qualification of alternate suppliers to preserve continuity of supply.

These dynamics have a downstream effect on both procurement strategies and clinical availability. Healthcare organisations are increasingly asking suppliers for greater transparency on total delivered cost, supplier concentration risk, and contingency plans. At the same time, product developers are exploring formulation changes that reduce reliance on tariff-exposed inputs or that enable localised production at lower scale. While tariffs can create short-term price pressure, they also incentivise investments in domestic capabilities and can catalyse partnerships focused on vertical integration and supply resilience. The net effect is a reorientation of commercial contracts toward flexibility clauses, longer-term supplier collaboration, and scenario-based inventory planning.

Insightful segmentation analysis that aligns dressing formats, antimicrobial chemistries, care settings, and wound types to clinical use cases and commercial pathways

Segmentation analysis reveals differentiated adoption patterns and development priorities across dressing format, antimicrobial agent, care setting, and wound type. By dressing type, stakeholders are evaluating alginate and foam for high-exudate wounds and considering film & sheet formats-further categorised into hydrocolloid film and transparent film-for low-exudate applications and discreet protection. Hydrogels, which include amorphous and sheet hydrogel variants, are gaining traction for autolytic debridement and pain-sensitive sites, while powder formats offer utility for cavity wounds and irregular geometries.

Agent selection remains a core determinant of performance claims, with honey and iodine historically valued for broad-spectrum activity and biocompatibility, and PHMB and silver positioned around controlled-release chemistries and established clinical datasets. End users exert distinct requirements: hospitals, including both private and public institutions, demand standardised supply, regulatory compliance, and proven clinical pathways; clinics prioritise usability and cost-efficiency; and home healthcare settings emphasise patient-friendly application and longer wear times. Wound type considerations-acute, burn, and chronic-further drive product specifications, as burn care centres often require specialised thermal compatibility and exudate management, whereas chronic wound management stresses long-term bioburden control and compression compatibility. Taken together, these segmentation layers inform product development roadmaps, reimbursement positioning, and go-to-market strategies.

Regional demand drivers and regulatory nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate differentiated commercial strategies

Regional dynamics exhibit divergent demand drivers and adoption velocities, shaped by healthcare infrastructure, procurement practices, and regulatory frameworks. In the Americas, established hospital networks and growing outpatient services are driving demand for a broad range of antimicrobial dressings, while buyers increasingly prioritise evidence-based products that reduce inpatient stays and readmission risk. Europe, Middle East & Africa presents a heterogeneous landscape: western European markets focus on clinical differentiation and stringent regulatory compliance, whereas many MEA markets are guided by cost-containment and supply security concerns, prompting interest in robust, easy-to-store dressing formats.

Asia-Pacific continues to be a region of rapid uptake due to expanding surgical volumes, rising awareness of infection control, and investments in home healthcare. Local manufacturing capabilities are strengthening across multiple countries, and regional procurement consortia are influencing pricing and distribution models. Across all regions, the trend toward outpatient and home-based care is universal, and this is driving manufacturers to consider packaging, patient instructions, and product stability under varied environmental conditions. Taken together, regional strategies must balance global standards with local regulatory nuances and distribution realities to achieve sustainable adoption.

Competitive dynamics driven by clinical evidence generation, strategic partnerships, and value-added service models that differentiate suppliers within wound care portfolios

The competitive landscape is characterised by a mixture of specialised medical dressing firms, diversified wound care divisions of larger healthcare companies, and emerging niche players focusing on novel antimicrobial chemistries. Leading organisations are doubling down on clinical evidence generation and post-market surveillance to substantiate claims of infection reduction and healing acceleration. Strategic partnerships with academic centres and large health systems are being used to generate real-world evidence and to create clinical pathways that support formulary inclusion.

Meanwhile, smaller innovators are competing on formulation novelty, ease of use, and targeted indications such as burn care or chronic wound management. Distribution and service models are evolving so that suppliers offer bundled solutions that combine dressings with training, telehealth follow-up, and adherence-support materials. Procurement teams are rewarding such integrated approaches because they reduce the administrative burden of product changes and improve patient outcomes. In this environment, firms that can demonstrate robust supply resilience, clinical validation, and comprehensive stakeholder support have a competitive edge in securing long-term institutional partnerships.

Actionable strategic priorities for manufacturers and purchasers that link clinical evidence, supply resilience, integrated services, and outcome-focused procurement

Industry leaders should prioritise a set of actionable moves that align commercial execution with clinical value and supply resilience. First, invest in pragmatic clinical evidence programmes that answer the specific questions hospital formulary committees and home healthcare providers ask about infection rates, wear time, and patient adherence. Evidence that is pragmatic, locally relevant, and tied to economic outcomes will be more persuasive than isolated laboratory data. Second, diversify sourcing and consider nearshoring critical inputs to mitigate tariff exposure and reduce lead time variability.

Third, develop integrated service propositions that include clinician training, patient education materials, and remote follow-up to increase successful adoption in outpatient and home settings. Fourth, align product portfolios with distinct care pathways across acute, burn, and chronic wound management so that sales efforts can be tailored to the clinical decision-making process. Finally, pursue collaborative arrangements with payers and health systems to pilot outcome-based procurement models that reward demonstrated reductions in infection rates and readmissions. By executing on these priorities, leaders will reinforce both clinical credibility and commercial durability.

A transparent and reproducible mixed-methods research framework combining clinical evidence synthesis, stakeholder interviews, and supply chain validation to support actionable insights

The research approach underpinning these insights combined a structured review of peer-reviewed clinical literature, regulatory guidance documents, and procurement policy statements, complemented by interviews with clinicians, procurement officers, and supply chain managers. Emphasis was placed on triangulating clinical claims with real-world implementation experiences and on validating supplier responses to recent tariff and supply disruptions. The methodological framework prioritised reproducibility and transparency, capturing both quantitative signals from public databases and qualitative nuance from frontline stakeholders.

Data collection included synthesis of published clinical trials, observational studies, and post-market surveillance summaries, while interviews explored adoption barriers, clinician preferences, and procurement criteria across hospitals, clinics, and home healthcare organisations. Findings were cross-checked for consistency across sources and contextualised regionally to reflect differences in regulatory regimes and care delivery models. Limitations and assumptions are documented in the full report to support informed interpretation and to identify areas for follow-up research and targeted data collection.

Strategic summary tying clinical innovation, procurement sophistication, and supply resilience to the long-term adoption of antimicrobial dressing solutions

In sum, antimicrobial dressings remain a critical tool in infection prevention and wound management, yet their future trajectory will be shaped by the convergence of clinical evidence requirements, supply chain resilience imperatives, and evolving care delivery models. Innovations in agent chemistry and dressing formats are expanding therapeutic options, while regulatory scrutiny and procurement sophistication are raising the evidentiary bar for widespread adoption. The decentralisation of care toward clinics and home healthcare settings is a durable trend that will continue to influence product design priorities and commercial approaches.

Organisations that invest in practical clinical programmes, diversify sourcing, and offer integrated service bundles will be better positioned to secure durable relationships with health systems and payers. At the same time, tariff and trade shifts underscore the importance of flexible manufacturing and supplier transparency. Moving forward, alignment between product development, evidence generation, and distribution strategy will determine which solutions become standard of care across acute, burn, and chronic wound pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimicrobial Dressings Market, by Dressing Type

  • 8.1. Alginate
  • 8.2. Film & Sheet
    • 8.2.1. Hydrocolloid Film
    • 8.2.2. Transparent Film
  • 8.3. Foam
  • 8.4. Gel
  • 8.5. Hydrogel
    • 8.5.1. Amorphous Hydrogel
    • 8.5.2. Sheet Hydrogel
  • 8.6. Powder

9. Antimicrobial Dressings Market, by Agent Type

  • 9.1. Honey
  • 9.2. Iodine
  • 9.3. Silver

10. Antimicrobial Dressings Market, by Wound Type

  • 10.1. Acute Wounds
  • 10.2. Burn Wounds
  • 10.3. Chronic Wounds

11. Antimicrobial Dressings Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Antimicrobial Dressings Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antimicrobial Dressings Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antimicrobial Dressings Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Antimicrobial Dressings Market

16. China Antimicrobial Dressings Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3M Company
  • 17.6. B. Braun Melsungen AG
  • 17.7. Cardinal Health
  • 17.8. Coloplast A/S
  • 17.9. ConvaTec Group plc
  • 17.10. Essity AB
  • 17.11. MedCu Technologies Ltd.
  • 17.12. Medline Industries, LP
  • 17.13. Molnlycke AB
  • 17.14. Paul Hartmann AG
  • 17.15. Smith & Nephew plc
  • 17.16. Solventum Corporation
  • 17.17. Urgo Medical SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIMICROBIAL DRESSINGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTIMICROBIAL DRESSINGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTIMICROBIAL DRESSINGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY ALGINATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY ALGINATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY ALGINATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROCOLLOID FILM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROCOLLOID FILM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROCOLLOID FILM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY TRANSPARENT FILM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY TRANSPARENT FILM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY TRANSPARENT FILM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FOAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FOAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FOAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AMORPHOUS HYDROGEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AMORPHOUS HYDROGEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AMORPHOUS HYDROGEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY SHEET HYDROGEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY SHEET HYDROGEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY SHEET HYDROGEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HONEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HONEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HONEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY IODINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY IODINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY IODINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY SILVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY SILVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY SILVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY ACUTE WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY ACUTE WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY ACUTE WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY BURN WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY BURN WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY BURN WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY CHRONIC WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY CHRONIC WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 173. G7 ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 174. G7 ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. G7 ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NATO ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. NATO ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ANTIMICROBIAL DRESSINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ANTIMICROBIAL DRESSINGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ANTIMICROBIAL DRESSINGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY DRESSING TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY FILM & SHEET, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HYDROGEL, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY WOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA ANTIMICROBIAL DRESSINGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)